Research programme: eye surgery therapeutics - Schering-PloughAlternative Names: rAd-p21
Latest Information Update: 24 Aug 2009
At a glance
- Originator Schering-Plough; University of Wisconsin-Madison
- Class Gene therapies
- Mechanism of Action Angiogenesis inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Wounds
Most Recent Events
- 24 Aug 2009 Discontinued - Preclinical for Wounds in USA (unspecified route)